Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

PJ Online | News: Aspirin and warfarin no better than aspirin alone

Home > PJ > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 268 No 7185 p197-203
16 February 2002

This article
Reprint
Photocopy


News summary


Aspirin and warfarin no better than aspirin alone

There is no reduction in mortality, stroke, or recurrent myocardial infarction in patients treated with a combination of aspirin and warfarin compared with those treated with aspirin alone, say researchers.

Dr Louis Flore, Veteran Affairs Boston Healthcare System, Massachusetts, and colleagues conducted an open-label trial to determine whether a combination of aspirin and warfarin would be more effective than aspirin monotherapy for secondary prevention of vascular events and death after acute myocardial infarction (AMI). The trial involved 5,059 patients, of whom 2,537 received 162mg aspirin daily and 2,522 received warfarin (target INR 1.5?2.5IU) plus 81mg aspirin daily. All patients had suffered an AMI within the previous 14 days and were followed up for a median of 2.7 years.

The researchers found that 17.3 per cent of patients in the aspirin group and 17.6 per cent of patients in the combination group died. Recurrent MI or stroke occurred in 13.1 and 3.5 per cent of patients in the aspirin group compared with 13.3 and 3.1 per cent of patients in the combination therapy group.

Although the annual incidence of major bleeding episodes (mainly gastrointestinal) was low, levels in the combination group were higher than those in the aspirin group (P<0.001), say the researchers. The incidence of intracranial haemorrhage was equal in both groups, with fatal haemorrhage occurring in seven patients from the aspirin group and 10 patients from the combination group.

The authors conclude that in post myocardial infarction patients, warfarin therapy combined with low dose aspirin does not provide a clinical benefit beyond that achievable by aspirin alone (Circulation 2002;105:557).

Back to Top


Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20006042

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.

Visit rpharms.com

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.